Why the study?
Reports of thrombocytopenic toxicity associated with novel oral anticoagulants are limited.
Does rivaroxaban cause acute thrombocytopenia in patients with atrial fibrillation?
Does rivaroxaban cause acute thrombocytopenia in patients with atrial fibrillation?
Rivaroxaban may rarely induce acute thrombocytopenia, highlighting the need for platelet monitoring at the initiation of NOAC therapy in elderly patients.
Answers are grounded in this paper and cite their sources.
Rivaroxaban may rarely cause thrombocytopenia; case report leaves open incidence, causality, and need for confirmation.
BACKGROUND: Novel oral anticoagulants (NOACs) are commonly used for the anticoagulation of patients with atrial fibrillation. Reports of thrombocytopenic toxicity of NOACs are limited. In this report, we present a case of thrombocytopenia likely induced by rivaroxaban, which is an extremely rare adverse drug reaction. CASE SUMMARY: /L. After the cessation of rivaroxaban, the platelet count returned to normal. The patient was diagnosed with thrombocytopenia, which was likely induced by rivaroxaban. The incidence of thrombocytopenic toxicity of NOACs is extremely low. CONCLUSION: Thrombocytopenia during anticoagulation therapy may be associated with a high risk of life-threatening bleeding. For elderly patients, changes in platelet count should be carefully monitored at the beginning of NOAC treatment, and we should be on the alert for bleeding events as well.
No takes yet. Share an insight, caveat, or question.
He et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: